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Background: HIF-1 (hypoxia-inducible factor 1) is a transcriptional activator that functions as a critical regulator of
oxygen homeostasis. Recently, a large number of epidemiological studies have investigated the relationship
between HIF-1α C1772T/G1790A polymorphisms and cancer susceptibility. However, the results remain inconclusive.
Therefore, we performed a meta-analysis on all of the available case-control studies to systematically summarize the
possible association.
Methods: A literature search was performed using PubMed and the Web of Science database to obtain relevant
published studies. Pooled odds ratios (ORs) and corresponding 95% confidence intervals (CIs) for the relationship
between HIF-1α C1772T/G1790A polymorphisms and cancer susceptibility were calculated using fixed- and
random-effects models when appropriate. Heterogeneity tests, sensitivity analyses and publication bias assessments
were also performed in our meta-analysis.
Results: A total of 40 studies met the inclusion criteria were included in the meta-analysis: 40 studies comprised of
10869 cases and 14289 controls for the HIF-1α C1772T polymorphism and 30 studies comprised of 7117 cases
and 10442 controls for the HIF-1α G1790A polymorphism. The results demonstrated that there were significant
association between the HIF-1α C1772T polymorphism and cancer susceptibility under four genetic models
(TT vs. CC: OR = 1.63, 95% CI = 1.02-2.60; CT + TT vs. CC: OR = 1.15, 95% CI = 1.01-1.34; TT vs. CT + CC: OR = 2.11,
95% CI = 1.32-3.77; T vs. C: OR = 1.21, 95% CI = 1.04-1.41). Similarly, the statistically significant association between
the HIF-1α G1790A polymorphism and cancer susceptibility was found to be consistently strong in all of the genetic
models. Moreover, increased cancer risk was observed when the data were stratified by cancer type, ethnicity and
the source of controls.
Conclusions: This meta-analysis demonstrates that both the C1772T and G1790A polymorphisms in the HIF-1α
gene likely contribute to increased cancer susceptibility, especially in the Asian population and in breast cancer,
lung cancer, pancreatic cancer and oral cancer. However, further research is necessary to evaluate the relationship
between these polymorphisms and cancer risk.
Keywords: HIF-1 gene, Polymorphism, Cancer, Susceptibility, Meta-analysis* Correspondence: zhaopeng@njmu.edu.cn; aihuagu@njmu.edu.cn
†Equal contributors
Department of Neurosurgery, The First Affiliated Hospital, Nanjing Medical
University, 300 Guangzhou Road, Nanjing 210029, China
© 2014 Yan et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited.
Yan et al. BMC Cancer 2014, 14:950 Page 2 of 16
http://www.biomedcentral.com/1471-2407/14/950Background
Human cancer is a major cause of death in the world,
and it is estimated that the number of new cases will
increase to more than 15 million in the coming decade,
creating a substantial worldwide public health burden
[1,2]. Various factors, such as genetic and environmental
influences, are associated with cancer prognosis. How-
ever, the exact etiology and mechanism of carcinogenesis
have not yet been clearly elucidated. In recent years, it
has become well-accepted that intrinsic factors, such as
host genetic susceptibility, may play important roles in
the process of cancer development [3,4], and an increa-
sing number of studies have focused on the association
between genetic factors and cancer susceptibility.
Hypoxia-inducible factor 1 (HIF-1) is a transcriptional
activator that functions as a critical regulator of oxygen
homeostasis. It is a heterodimer composed of two subunits,
HIF-1α and HIF-1β, which dimerize and bind to DNA via
the basic helix-loop-helix Per/Arnt/Sim (bHLH-PAS) do-
main [5,6]. HIF-1α expression is induced in hypoxic cells,
and its level exponentially increase when the cells are ex-
posed to O2 concentration of less than 6%. Under hypoxic
condition, HIF-1α ubiquitination decreases dramatically,
resulting in an accumulation of the protein, while under
normoxic condition, HIF-1α is rapidly degraded through
von Hippel-Lindau (VHL)-mediated ubiquitination and
proteasomal degradation [7-10]. HIF-1 has also been sug-
gested to play an important role in tumor development,
progression and metastasis, and HIF-1 can activate the
transcription of more than 60 target genes that are in-
volved in crucial aspects of cancer establishment, inclu-
ding cell survival, glucose metabolism, angiogenesis and
invasion [11,12].
The HIF-1α gene is located on chromosome 14q21-24,
and recent studies have shown that there are a total of 35
common single nucleotide polymorphisms (SNPs) through-
out the HIF-1α gene in Caucasian and Asian population
[13-15]. Two important SNPs in exon 12 of the HIF-1
gene, HIF-1α C1772T (rs11549465) and HIF-1α G1790A
(rs11549467), lead to amino acid substitution of proline to
serine at position 582 and alanine to threonine at position
588 of the protein, respectively [8,16,17]. These two poly-
morphisms have been demonstrated to be functionally
meaningful, resulting in increased transcriptional activity
of HIF-1α [14,18]. Previous studies have shown that the
overexpression of HIF-1α is significantly associated with
cell proliferation, increased tumor susceptibility, tumor
size, lymph node metastasis and prognosis [19,20].
In recent years, the HIF-1α gene has been a research
focus in the scientific community, and many epidemio-
logical studies have been performed to assess the associa-
tion between HIF-1α C1772T/G1790A polymorphisms
and cancer susceptibility. However, the results of the
different studies are conflicting. Hence, we performed ameta-analysis of all of the eligible studies to clarify the role
of HIF-1α C1772T/G1790A polymorphisms in cancer
development.
Methods
Study eligibility and validity assessment
We performed a computerized literature search of the
PubMed and Web of Science databases to identify all of
the relevant studies of cancer that contained sufficient
genotyping data for at least one of the two polymor-
phisms, HIF-1α C1772T or HIF-1α G1790A. The search
strategy was designed by two researchers and included
the following keywords: “HIF-1 OR hypoxia-inducible
factor-1” and “polymorphism”, and the last search was
updated on September 20th, 2013. To obtain all eligible
publications, we also manually reviewed the references
of the selected articles to identify other potential eligible
publications. Articles investigating the association bet-
ween cancer risk and the HIF-1α polymorphisms were
identified with no language restriction.
Inclusion criteria
The studies selected were required to meet the following
criteria: 1) evaluate the association between the HIF-1α
C1772T and/or HIF-1α G1790A polymorphisms and
cancer risk; 2) use a human case-control design; 3) con-
tain sufficient published data for the estimation of an
odds ratio (OR) with a 95% confidence interval (CI).
Data extraction
Data were extracted from all of the eligible publications by
two investigators (Yan and Chen) independently, accor-
ding to the inclusion criteria listed above. Disagreements
between the two investigators were resolved by discussion
until a consensus was reached. The following information
was extracted from each of the included publications:
the first author’s name, publication data, country of
origin, ethnicities of the sample population (categorised as
Asians, Caucasians and Mixed), cancer type, source of
control group (population- or hospital-based controls),
total number of cases and controls, and the number of
cases and controls with the HIF-1α C1772T/G1790A
polymorphisms.
Statistical methods
The strength of the association between the HIF-1α
C1772T/HIF-1α G1790A polymorphisms and cancer risk
was measured by ORs with 95% CIs. The statistical
significance of the pooled OR was calculated by the Z test,
a P < 0.05 was considered to be statistically significant
(P-values were two sided). For HIF-1α C1772T poly-
morphism, we examined the overall ORs and compared
the cancer incidence using the allelic model (T versus C),
homozygote model (TT versus CC), heterozygote model
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recessive model (TT versus TC +CC). For HIF-1α G1790A
polymorphism, we evaluated the risk in the allelic model
(A versus G), homozygote model (AA versus GG), hetero-
zygote comparison model (GA versus GG), dominant
models (AA +AG versus GG), and recessive model (AA
versus AG+GG). Subgroup analyses were also conducted
by ethnicity, cancer type (“other cancer groups” means
any cancer types with less than two separate publications)
and source of controls. Statistical heterogeneity was esti-
mated by a chi-square based Q-test, and when P < 0.05,
the heterogeneity was considered to be significant. We
combined all of the values from each individual study
using the fixed-effect model and the random-effect model.
When P > 0.05, the effects were assumed to be homo-
genous, and the fixed-effect model (the Mantel-Haenszel
method) was used [21]. When P < 0.05, the random-effect
model (the DerSimonian and Laird method) was more
appropriate [22]. The inter-study variance I2 (I2 = 100% ×
(Q-df)/Q) was used to quantitatively estimate the hetero-
geneity, and the percentage of I2 was used to describe the
extent of the heterogeneity, I2 < 25%, 25-75% and >75%
represent low, moderate and high inconsistency, respect-
ively [23,24]. In addition, we performed sensitivity analyses
to evaluate the potential biases of the results in our meta-
analyses. The Hardy-Weinberg equilibrium (HWE) of
the controls for each study was also calculated using a
goodness-of-fit test (chi-square or Fisher’s exact test) and
P < 0.05 was considered to be statistically significant.
Sensitivity analyses were carried out to assess the stability
of the results by conducting analysis of studies with con-
trols in HWE. Finally, the Begg’s funnel plot and Egger’s
test were utilised to estimate the publication bias [25]. All
analyses were conducted by the software Stata (Version
11; Stata Corporation, College Station, Texas, USA). All
P-values were two-sided and a P of < 0.05 was considered
to be statistically significant.
Results
Studies selected
Through the literature search and selection, a total of 40
eligible studies met the inclusion criteria and were in-
cluded in our meta-analysis. One study (Konac et al.)
[26] provided data on three types of cancer (cervical
cancer, ovarian cancer, and endometrial cancer) and
both polymorphisms; therefore, we have grouped them
as one in the meta-analyses of all subjects except when
stratified by cancer type. Thus, each type of cancer in
this study was treated as a separated study in sub-group
analyses. Among the 40 eligible studies, 40 studies,
representing 10869 cases and 14289 controls, were
ultimately analyzed for the HIF-1α C1772T poly-
morphism [8,17,26-63], and 30 studies, representing
7177 cases and 10442 controls, were analyzed for theHIF-1α G1790A polymorphism [8,17,26,29-31,33-35,37-43,
45-48,50,52-57,59,62,63]. The literature search and study
selection procedure are shown in Figure 1. Of the 40 stu-
dies on the HIF-1α C1772T polymorphism, 6 studies were
conducted on prostate cancer, 6 studies on breast cancer,
3 studies on lung cancer, 4 studies on colorectal cancer, 4
studies on renal cancer, 4 studies on oral cancer and 12
studies on other cancers. Among these eligible studies, 20
were studies on Asians, 16 were studies on Caucasians
and 4 studies were performed on a population of mixed
ethnicity. The control sources were population-based in 17
studies and hospital-based in 23 studies. For the HIF-1α
G1790A polymorphism, 15 of the 30 eligible studies were
performed in Asian populations, 13 studies were per-
formed in Caucasian populations and 2 studies were per-
formed in a mixed ethnicity population. Of these studies,
4 studies were conducted on breast cancer, 3 studies on
lung cancer, 4 studies on oral cancer, 3 studies on prostate
cancer, 3 studies on cervical cancer, 2 studies on pan-
creatic cancer, 2 studies on colorectal cancer, 4 studies on
renal cancer and 7 studies on other cancers. The control
sources were population-based in 17 studies and hospital-
based in 13 studies. The genotype frequency data of the
HIF-1α C1772T and HIF-1α G1790A polymorphisms
were extracted from all of these eligible publications. For
the HIF-1α C1772T polymorphism, the distributions of
the genotypes in the control groups in 11 studies were not
in HWE [17,50,51,53,54,56-58,60-62]. For the HIF-1α
G1790A polymorphism there was 1 study not in HWE
[62]. The main characteristics of the eligible studies in the
meta-analysis are listed in Table 1.
Quantitative data synthesis
For the HIF-1α C1772T polymorphism, the overall results
from the eligible studies demonstrated a significant associ-
ation between the HIF-1α C1772T polymorphism and an
increased cancer risk in four genetic models (TT vs. CC:
OR = 1.63, 95% CI = 1.02-2.60; CT + TT vs. CC: OR = 1.15,
95% CI = 1.01-1.34; TT vs. CT +CC: OR = 2.11, 95% CI =
1.32-3.77; T vs. C: OR = 1.21, 95% CI = 1.04-1.41). In the
subgroup analysis by cancer type, the HIF-1α C1772T
polymorphism significantly increased the risk of breast
cancer in Asians (TT vs. CC: OR = 4.42, 95% CI = 1.60-
12.21; TT vs. CT +CC: OR = 4.16, 95% CI = 1.51-11.48; T
vs. C: OR = 1.28, 95% CI = 1.05-1.55), other cancers (TT
vs.CC: OR = 3.18, 95% CI = 1.90-5.32; TT vs. CT +CC:
OR= 3.31, 95% CI = 1.98-5.53; T vs. C: OR= 1.47, 95% CI =
1.10-1.96) and lung cancer (TT vs. CT +CC: OR = 3.27,
95% CI = 1.73-6.17 ). When the data was stratified by
ethnicity, the HIF-1α C1772T polymorphism was sig-
nificantly correlated with an increased cancer risk in
Asian population (TT vs. CC: OR = 4.10, 95% CI = 2.49-
6.76; CT + TT vs. CC: OR = 1.29, 95% CI = 1.04-1.58;
TT vs. CT +CC: OR = 3.67, 95% CI = 2.23-6.02; T vs.
Figure 1 Study flow-chart illustrating the literature search and eligible study selection process.
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tion (TT vs. CT +CC: OR = 1.95, 95% CI = 1.14-3.31). In
the analysis stratified by the sources of controls, a signifi-
cant association was observed in the hospital-based group
(CT +TT vs. CC: OR = 1.28, 95% CI = 1.01-1.62; T vs.
C: OR = 1.33, 95% CI = 1.04-1.71) and the population-based
group (TT vs. CT+CC: OR= 2.01, 95% CI = 1.10-3.71).
Sensitivity analyses were carried out to assess the stability
of the results by conducting analyses of studies with con-
trols in HWE. The results showed significantly increased
cancer risk (TT vs. CC: OR = 2.47, 95% CI = 1.81-3.36;
CT + TT vs. CC: OR = 1.25, 95% CI = 1.05-1.49; TT vs.
CT + CC: OR = 2.43, 95% CI = 1.41-4.19; T vs. C: OR =
1.27, 95% CI = 1.06-1.52). The other results for the HIF-1α
C1772T polymorphism were similar to those when the
studies with controls not in HWE were included. The
main results of this pooled analysis are shown in Table 2.
Figure 2 shows the forest plot of the association between
cancer risk and the HIF-1α C1772T polymorphism under
the allelic model.
For HIF-1α G1790A polymorphism, as shown in Table 3,
the association between the HIF-1α G1790A polymorphism
and increased cancer risk was significant for the pooled ORs
under all of the genetic models (AA vs. GG: OR= 5.11, 95%
CI = 2.08-12.56; GA vs. GG: OR= 1.45, 95% CI = 1.05-1.99;
AA +AG vs. GG: OR = 1.63, 95% CI = 1.16-2.30; AA vs.
GA+GG: OR = 4.41, 95% CI = 1.80-10.84; A vs. G: OR =
1.77, 95% CI = 1.23-2.25). In the subgroup analysis by
cancer type, a significant association was observed in lung
cancer (AA vs. GG: OR = 5.42, 95% CI = 2.74-10.70; GA vs.
GG: OR= 1.72, 95% CI = 1.22-2.41; AA +AG vs. GG: OR =
2.14, 95% CI = 1.56-2.94; AA vs. GA+GG: OR = 4.52, 95%CI = 2.31-8.83; A vs. G: OR = 2.27, 95% CI = 1.74-2.95),
pancreatic cancer (AA+AG vs. GG: OR= 3.14, 95% CI =
1.99-2.97; A vs. G: OR = 3.08, 95% CI = 1.98-4.78) and renal
cancer (AA vs. GA+GG: OR= 3.09, 95% CI = 1.38-6.92).
When the data were stratified by ethnicity, significantly
increased cancer risk was observed in Asian population and
Caucasian population. When the studies were stratified by
the source of controls, a significant association was ob-
served for population-based controls under the homo-
zygote model, the dominant comparison model and the
allelic model. Sensitivity analyses were conducted after the
removal of the studies with controls not in HWE, the
results for the HIF-1α G1790A polymorphism were similar
to those when the studies with controls not in HWE were
included. Table 3 shows the main results of this pooled
analysis for the HIF-1α G1790A polymorphism. Figure 3
shows the forest plot of the association between cancer risk
and the HIF-1α G1790A polymorphism under the do-
minant model.
Test of heterogeneity
There was significant heterogeneity observed in the
allelic comparison model, the dominant comparison
model and the heterozygote comparison model (Tables 2
and 3), and the heterogeneity was effectively decreased
or removed in the subgroups stratified by ethnicity,
cancer types and source of controls (Tables 2 and 3).
Sensitivity analysis
We performed sensitivity analysis by removing each in-
dividual study (including the restudies with controls not
in HWE) sequentially for both the HIF-1α C1772T and
Table 1 Characteristics of studies included in the meta-analysis
First
author






Cases Controls Case Control HWE
MM MW WW MM MW WW
Clifford 2001 UK Caucasian Renal C1772T PB 48 143 42 6 0 110 27 6 0.02
G1790A PB 48 144 47 1 0 140 4 0 0.87
Tanimoto 2003 Japan Asian HNSCC C1772T PB 55 110 45 10 0 98 12 0 0.55
G1790A PB 55 110 51 4 0 101 9 0 0.65
Kuwai 2004 Japan Asian Colorectal C1772T PB 100 100 100 0 0 89 11 0 0.56
Ollerenshaw 2004 UK Caucasian Renal C1772T PB 160 162 16 54 90 1 90 71 0.001
G1790A PB 146 288 65 67 14 239 39 10 0.001
Ling 2005 China Asian Esophageal C1772T HB 95 104 84 11 0 93 11 0 0.57
Chau 2005 USA Caucasian Prostate C1772T PB 196 196 161 29 6 179 14 3 0.002
Fransen 2006 Sweden Caucasian Colorectal C1772T PB 198 258 167 28 3 213 43 2 0.92
Fransen 2006 Sweden Caucasian Colorectal G1790A PB 198 256 189 9 0 247 9 0 0.77
Konac 2007 Turkey Caucasian Cervical C1772T HB 32 107 10 14 8 68 37 2 0.23
G1790A HB 32 107 32 0 0 107 0 0 0.99
Caucasian Ovarian C1772T HB 49 107 34 14 1 68 37 2 0.23
G1790A HB 49 107 47 2 0 107 0 0 0.99
Caucasian Endometrial C1772T HB 21 107 4 12 5 68 37 2 0.23
G1790A HB 21 107 21 0 0 107 0 0 0.99
Li 2007 USA mixed Prostate C1772T PB 1041 1234 818 209 14 995 221 18 0.16
G1790A PB 1066 1264 1053 13 0 1247 17 0 0.81
Orr-Urtreger 2007 Israel Caucasian Prostate C1772T PB 402 300 287 99 16 217 80 3 0.14
G1790A PB 200 300 198 2 0 298 2 0 0.95
Apaydin 2008 Turkey Caucasian Breast C1772T PB 102 102 79 21 2 68 29 5 0.42
G1790A PB 102 102 102 0 0 98 4 0 0.84
Lee 2008 Korea Asian Breast C1772T PB 1332 1369 1207 119 6 1245 123 1 0.25
Kim 2008 Korea Asian Breast C1772T HB 90 102 81 8 1 93 9 0 0.64
G1790A HB 90 102 87 3 0 94 7 1 0.06
Nadaoka 2008 Japan Asian Bladder C1772T HB 219 461 197 21 1 419 42 0 0.35
G1790A HB 219 461 204 13 2 421 40* - 0.46
Jacobs 2008 USA mixed Prostate C1772T HB 1420 1450 1156 252 12 1138 284 28 0.04
Horree 2008 Netherland Caucasian Endometrial C1772T PB 58 559 50 5 3 463 84 12 0.01
Naidu 2009 Malaysia Asian Breast C1772T PB 410 275 294 100 16 222 50 3 0.92
G1790A PB 410 275 332 72 6 232 41 2 0.90
Chen 2009 Taiwan Asian Oral C1772T PB 174 347 163 10 1 334 13 0 0.72
G1790A PB 174 347 153 20 1 333 14 0 0.70
Konac 2009 Turkey Caucasian Lung C1772T PB 141 156 110 31 0 111 43 2 0.34
G1790A PB 141 156 141 1 0 154 2 0 0.94
Morris 2009 UK Caucasian Renal C1772T PB 332 313 290 39 3 262 46 5 0.08
G1790A PB 325 309 313 10 2 294 15 0 0.66
Foley 2009 Ireland Caucasian Prostate C1772T PB 95 188 65 30 0 175 13 0 0.62
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Table 1 Characteristics of studies included in the meta-analysis (Continued)
Li 2009 China Asian Gastric C1772T HB 87 106 83 4 0 93 13 0 0.50
G1790A HB 87 106 74 13 0 100 6 0 0.76
Munoz-
Guerra 2009 Spain Caucasian Oral C1772T PB 70 148 57 6 7 113 27 8 <0.01
G1790A PB 64 139 40 21 3 130 9 0 0.69
Kim 2010 Korea Asian Cervical C1772T HB 199 214 177 22 0 187 27 0 0.32
G1790A HB 199 213 187 12 0 200 12 1 0.10
Shieh 2010 Taiwan Asian Oral C1772T HB 305 96 282 23 0 89 7 0 0.71
G1790A HB 305 96 281 24 0 89 7 0 0.71
Knechtal 2010 Austria Caucasian Colorectal C1772T PB 368 2156 291 77** - 1773 383* - >0.05
G1790A PB 367 2156 356 11* - 2080 76* - >0.05
Hsiao 2010 Taiwan Asian Hepatocellul-
ar
C1772T HB 102 347 94 8 0 334 13 0 0.72
G1790A HB 102 347 87 15 0 333 14 0 0.70
Xu 2011 China Asian Glioma C1772T HB 150 150 121 27 2 135 14 1 0.35
Putra 2011 Japan Asian Lung C1772T PB 83 110 74 9 0 98 12 0 0.55
G1790A PB 83 110 72 9 2 101 9 0 0.65
Kang 2011 Korea Asian Colorectal C1772T PB 50 50 46 4** - 38 12** - <0.01
Wang 2011 China Asian Pancreatic C1772T HB 263 271 209 54 0 242 29 0 0.35
G1790A HB 263 271 198 65 0 249 22 0 0.49
Zagouri 2012 Greece Caucasian Breast C1772T HB 113 124 98 15 0 107 17 0 0.41
Kuo 2012 Taiwan Asian Lung C1772T HB 285 300 153 94 38 216 73 11 0.13
G1790A HB 285 300 150 94 41 215 74 11 0.15
Qin 2012 China Asian Renal C1772T HB 620 623 572 46 2 578 43 2 0.22
G1790A HB 620 623 575 45 0 584 39 0 0.42
Li 2012 China Asian Prostate C1772T HB 662 716 612 48 2 659 57 0 0.27
G1790A HB 662 716 614 47 1 685 31 0 0.55
Alves 2012 Brazil mixed Oral C1772T PB 40 88 0 1 39 0 85 3 <0.01
G1790A PB 40 88 2 1 37 81 7 0 0.70
Ruiz-Tovar 2012 Spain Caucasian Pancreatic C1772T PB 59 152 47 1 11 116 28 8 0.002
G1790A PB 59 152 54 2 3 142 10 0 0.68
Fu 2013 China Asian Cervical C1772T HB 518 553 467 49 2 492 60 1 0.55
G1790A HB 509 553 489 20 0 510 42 1 0.89
Ribeiro 2013 Portugal Caucasian Breast C1772T PB 96 74 74 21 1 61 7 4 0.001
G1790A PB 96 74 96 0 0 74 0 0 0.99
Mera-
Menendez 2013 Spain Caucasian Glottic
larynx C1772T HB 118 148 85 18 15 113 27 8 0.001
G1790A HB 111 139 107 4 0 130 9 0 0.69
Total C1772T 10869 14289 8994 1568 307 12181 1897 211
G1790A 7117 10442 6416 589 112 9922 494 26
W: wide type alleles (1772C or 1790G); M: mutant type alleles (1772 T or 1790A); HWE: Hardy-Weinberg Equilibrium; PB: population based; HB: hospital based.
Mixed: Caucasian and African-American; HNSCC: head and neck squamous cell carcinoma.
*Frequency of genotypes “AA + AG”; **Frequency of genotypes “TT + TC”.
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Table 2 Meta-analysis of the HIF-1α C1772T polymorphism and cancer risk
Variables TT vs. CC CT vs. CC CT + TT vs. CC TT vs. CT + CC T vs. C
Study Case/
control
I2 Phet OR (95% CI) Case/
control
I2 Phet OR (95% CI) Case/
control
I2 Phet OR (95% CI) case/
control
I2 Phet OR (95% CI) Case/
control
I2 Phet OR (95% CI)
Overall 40 9301/
12392
67 <0.001 1.63 (1.02-2.60)* 10562/
14078
68 <0.001 1.08 (0.92-1.26)* 10958/
14676
70 <0.001 1.15 (1.01-1.34)* 10540/
12470
71 <0.001 2.11 (1.32-3.37)* 21738/
28578





59 0.02 2.21 (1.27-3.83)* 8481/
11109
64 <0.001 1.15 (0.98-1.36)* 8604/
11556
70 <0.001 1.20 (1.02-1.41)* 8275/
9350
49 0.01 2.13 (1.28-3.55)* 17208/
22338





66 0.09 10.11 (2.55-40.05) 739/
871
60 0.08 0.98 (0.72-1.34) 749/
874
80 0.01 1.32 (0.61-2.87)* 749/
874
51 0.15 8.55 (2.28-32.13) 2369/
1748
88 <0.001 1.41 (0.59-3.35)*
Breast 6 1859/
1809
62 0.03 1.41 (0.34-5.75)* 2117/
2033
37 0.16 1.01 (0.91-1.33) 2143/
2046
46 0.1 1.13 (0.94-1.36) 2143/
2046
60 0.04 1.38 (0.35-5.46)* 4286/
4092





55 0.08 2.30 (1.08-4.91) 2022/
1963
35 0.19 1.07 (0.88-1.29) 2047/
1972
56 0.06 1.12 (0.92-1.35) 2047/
1972
49 0.12 2.27 (1.06-4.82) 4154/
3944





0 0.93 4.42 (1.60-12.21) 1809/
1742
36 0.21 1.14 (0.92-1.41) 1832/
1746
51 0.13 1.22 (0.99-1.49) 1832/
1746
0 0.91 4.16 (1.51-11.48) 3664/
3492
55 0.11 1.28 (1.05-1.55)
Lung 3 375/
438
75 0.04 1.41 (0.07-30.44)* 471/
553
75 0.02 1.13 (0.59-2.19)* 509/
566
86 0.01 1.19 (0.51-2.76)* 509/
566
71 0.07 3.27 (1.73-6.17) 1018/
1132
89 <0.001 1.19 (0.50-2.86)*
Colorectal 4 599/
2123
- - - 624/
2175
79 0.03 0.24 (0.01-5.51)* 627/
2177
71 0.02 1.12 (0.57-2.18)* 627/
2177
- - - 1254/
4354
80 0.02 0.26 (0.01-6.38)*
Prostate 6 3149/
3415
70 0.01 1.34 (0.54-3.31)* 3766/
4032
86 <0.001 1.34 (0.93-1.92)* 3816/
4084
87 <0.001 1.36 (0.95-1.96)* 3816/
4084
69 0.01 1.31 (0.54-3.20)* 7632/
8168





59 0.09 1.57 (0.89-2.75) 2168/
2417
88 <0.001 1.42 (0.84-2.40)* 2200/
2438
87 0.01 1.50 (0.89-2.40)* 2200/
2438
61 0.08 1.55 (0.89-2.72) 4400/
4876
85 <0.001 1.44 (0.93-2.21)*
Renal 4 1015/
1035
25 0.26 0.28 (0.12-1.28) 1065/
1157
74 0.01 0.62 (0.31-1.24)* 1160/
1241
70 0.02 0.62 (0.33-1.18)* 1160/
1241
21 0.29 1.37 (0.92-2.04) 2320/
2482





0 0.62 0.67 (0.21-2.13) 947/
929
13 0.28 0.92 (0.67-1.26) 952/
936
29 0.24 0.90 (0.67-1.22) 952/
936
0 0.64 0.69 (0.22-2.17) 1904/
1872
37 0.21 0.89 (0.67-1.19)
Oral 4 549/
547
0 0.46 2.01 (0.75-5.41) 542/
668
50 0.14 0.90 (0.55-1.47) 589/
679
16 0.3 1.04 (0.66-1.64) 589/
679
93 <0.001 22.82 (0.28-1887.72)* 1178/
1358





- - - 478/
443
0 0.5 1.28 (0.69-2.38) 479/
443
0 0.4 1.35 (0.73-2.49) 479/
443
- - - 958/
886
0 0.32 1.41 (0.78-2.56)
Other 12 1033/
2151
30 0.2 3.18 (1.90-5.32) 1190/
2445
67 <0.001 1.18 (0.79-1.78)* 1276/
2622
60 <0.001 1.34 (0.95-1.87)* 1276/
2622
0 0.52 3.31 (1.98-5.53) 2434/
4940





56 0.08 5.10 (1.72-15.07) 1032/
1758
60 0.01 1.47 (0.97-2.21)* 1041/
1763
64 0.01 1.52 (0.99-2.34)* 1041/
1763
24 0.27 4.47 (1.53-13.00) 2082/
3526




0 0.96 4.10 (2.49-6.76) 5678/
6335
50 0.01 1.20 (0.99-1.46)* 5787/
6400
75 <0.001 1.29 (1.04-1.58)* 5787/
6400
0 0.98 3.67 (2.23-6.02) 11574/
12800
61 <0.001 1.28 (1.04-1.57)
Caucasian 16 1791/
4247
74 <0.001 1.54 (0.72-3.27)* 2220/
4781
76 <0.001 0.93 (0.65-1.33)* 2385/
4921
59 0.01 1.07 (0.80-1.43)* 2385/
4921
58 0.003 1.95 (1.14-3.31)* 4770/
9842





76 <0.001 2.28 (0.62-8.35)* 1738/
3152
79 <0.001 1.20 (0.99-1.46)* 1776/
3535
82 <0.001 1.28 (0.88-1.86)* 1776/
3535
69 0.002 2.08 (0.68-6.37)* 3552/
7070





















77 <0.001 3.28 (1.29-8.30)* 5259/
6029
60 <0.001 1.18 (0.96-1.45)* 5348/
6086
72 <0.001 1.28 (1.01-1.62)* 5348/
6086
71 <0.001 2.85 (1.24-6.54)* 10696/
12172





35 0.13 4.88 (2.96-8.04) 3748/
4467
56 0.01 1.24 (0.99-1.57)* 3810/
4488
67 <0.001 1.33 (1.02-1.74)* 3810/
4488
4 0.4 4.23 (2.58-6.93) 7620/
8976
74 <0.001 1.38 (1.06-1.80)*
PB 23 4693/
5303
54 0.01 1.33 (0.76-2.31)* 5303/
7143
74 <0.001 0.99 (0.77-1.29)* 5521/
8203
70 <0.001 1.10 (0.89-1.36)* 5521/
8203
72 <0.001 2.02 (1.10-3.71)* 11042/
16406





49 0.04 1.51 (0.74-3.11)* 4733/
6642
72 <0.001 1.10 (0.85-1.43)* 4794/
6681
72 <0.001 1.17 (0.93-1.48)* 4794/
6681
46 0.63 1.51 (1.01-2.27) 9588/
13362
75 <0.001 1.14 (0.89-1.45)*


















Figure 2 Forest plot of the association between cancer risk and the HIF-1α C1772T polymorphism using the allelicmodel (T vs. C).
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http://www.biomedcentral.com/1471-2407/14/950the HIF-1α G1790A polymorphism (Figure 4 and
Additional file 1). The results indicated that the overall
significance of the pooled ORs was not altered by any
single study in the genetic models for the HIF-1α
C1772T/G1790A polymorphisms and cancer suscepti-
bility, suggesting stability and reliability in our overall
results.
Bias diagnostics
A Begg’s funnel plot and Egger’s test were used to assess
the publication bias in this meta-analysis. As shown in
Figure 5, for the HIF-1α C1772T polymorphism, the
funnel plots for the comparison of the five models ap-
pear to be basically symmetric. The Egger’s linear regres-
sion test did not show any evidence of significant
publication bias in five models (TT vs. CC: t = 0.50,
P = 0.62; TC vs. CC: t = -0.19, P = 0.85; TT vs. CT + CC:
t = 1.11, P = 0.28; T vs. C: t = 1.39, P = 0.17; CT + TT vs.
CC: t = 0.59, P = 0.56). For the HIF-1α G1790A poly-
morphism, no visual publication bias was detected in
the funnel plot (Figure 6) and the result showed nosignificant evidence of a publication bias in five models
(AA vs. GG: t = 0.03, P = 0.98; GA vs. GG: t = -0.86,
P = 0.40; AA vs. GA +GG: t = 0.33, P = 0.75; AA + AG vs.
GG: t = -0.40, P = 0.69; A vs. G: t = -0.41, P = 0.68).
Discussion
HIF-1 is a heterodimeric transcription factor and a key
regulator of the cellular response to hypoxia [5]. It is
composed of HIF-1α and HIF-1β subunits, which are
members of the bHLH-PAS transcription factor family.
HIF-1α is a unique O2-regulated subunit that determines
the function of HIF-1. HIF-1α upregulates the expres-
sion of genes whose protein products function to in-
crease O2 availability or to allow metabolic adaptation to
O2 deprivation, including VEGF, Epo, NOS2 and others.
Most of these aforementioned proteins have been impli-
cated in tumor development and progression [35,64,65].
Recent studies have reported that the overexpression of
HIF-1α is significantly associated with cell proliferation,
tumor susceptibility, tumor size, lymph node metastasis
and prognosis [12,35,66]. The HIF-1α gene is located on
Table 3 Meta-analysis of the HIF-1α G1790A polymorphism and cancer risk
Variables AA vs. GG GA vs. GG AA + AG vs.GG AA vs.GA + GG A vs. G
Study Case/
control
I2 Phet OR (95% CI) Case/
control
I2 Phet OR (95% CI) Case/
control
I2 Phet OR (95% CI) Case/
control
I2 Phet OR (95% CI) Case/
control
I2 Phet OR (95% CI)
Overall 30 6538/
9948
57 0.01 5.11 (2.08-12.56)* 7005/
10442
77 <0.001 1.45 (1.05-1.99)* 7117/
10442
83 <0.001 1.63 (1.16-2.30)* 7117/
10442
58 0.01 4.41 (1.80-10.84)* 14234/
20884





61 0.003 5.14 (1.67-15.86)* 6873/
10138
69 <0.001 1.35 (1.01-1.81)* 6971/
10154
79 <0.001 1.53 (1.10-2.12)* 6971/
10154
60 0.004 4.80 (1.58-14.55)* 13942/
20308





0 0.34 1.44 (0.38-5.44) 692/
550
53 0.12 1.03 (0.70-1.52) 698/
553
60 0.08 1.05 (0.72-1.53) 698/
553
0 0.36 1.41 (0.37-5.40) 1396/
1466
65 0.56 1.07 (0.76-1.52)
Cervical 3 708/
819
0 0.99 0.35 (0.04-3.39) 740/
871
57 0.13 0.62 (0.40-0.98) 740/
837
51 0.15 0.60 (0.38-0.94) 740/
837
0 0.99 0.36 (0.04-3.450 1480/
1746
42 0.19 0.59 (0.38-0.91)
Oral 4 517/
633
75 0.02 72.11 (2.08-2502.44)* 542/
670
70 0.02 3.17 (1.26-7.92)* 583/
670
92 <0.001 7.92 (1.58-39.64)* 583/
670
75 0.02 58.05 (1.70-1985.77)* 1166/
1340
96 0.01 9.66 (1.31-71.15)*
Prostate 3 1866/
2230
- - - 1927/
2280
1 0.37 1.42 (0.97-2.07) 1928/
2280
7 0.34 1.44 (0.98-2.10) 1928/
2280
- - - 3856/
4560
10 0.33 1.45 (0.99-2.11)
Renal 4 1016/
1267
0 0.95 5.10 (2.21-11.73) 1123/
1354
92 <0.001 1.51 (0.45-5.05)* 1139/
1364
92 <0.001 1.58 (0.49-5.04)* 1139/
1364
0 0.76 3.09 (1.38-6.92) 2278/
2728





- - - 991/
1076
0 0.42 1.00 (0.69-1.47) 993/
1076
0 0.6 1.04 (0.71-1.52) 993/
1076
- - - 1986/
2152
0 0.78 1.07 (0.74-1.55)
Lung 3 405/
481
0 0.87 5.42 (2.74-10.70) 466/
555
0 0.57 1.72 (1.22-2.41) 509/
566
0 0.46 2.14 (1.56-2.94) 509/
566
0 0.79 4.52 (2.31-8.83) 1018/
1132
0 0.48 2.27 (1.74-2.95)
Colorectal 2 545/
2327
- - - 554/
2336
- - - 554/
2336
0 0.45 0.97 (0.57-1.63) 554/
2336





- - - 319/
423
82 0.02 1.61 (0.24-10.76)* 322/
423
63 0.1 3.14 (1.99-4.97) 322/
423
- - - 644/
846
0 0.42 3.08 (1.98-4.78)
Other 7 593/
1377
- - - 642/
1377
74 <0.001 1.53 (0.65-3.59)* 644/
1377
72 <0.001 1.57 (0.70-3.53)* 644/
1377
- - - 1288/
2754




13 0.33 3.50 (2.05-5.98) 4010/
4614
74 <0.001 1.44 (1.04-1.99)* 4063/
4630
76 <0.001 1.49 (1.07-2.08)* 4063/
4630
0 0.45 3.12 (1.83-5.32) 8126/
9260
77 <0.001 1.49 (1.08-2.05)*
Caucasian 13 1829/
4357
0 0.69 6.63 (3.11-14.12) 1926/
4450
81 <0.001 1.36 (0.58-3.19)* 1948/
4460
82 <0.001 1.45 (0.69-3.04)* 1948/
4460
0 0.49 4.21 (2.04-8.71) 3896/
8920





0 0.74 12.40 (2.19-70.22) 1794/
4172
68 0.01 1.10 (0.48-2.49)* 1802/
4172
67 0.01 1.22 (0.62-2.37)* 1802/
4172
0 0.79 11.37 (2.02-63.93) 3604/
8344




45 0.12 1.54 (0.35-6.70) 3510/
4234
77 <0.001 1.37 (0.92-2.05)* 3554/
4248
79 <0.001 1.40 (0.93-2.11)* 3554/
4248
35 0.19 3.13 (1.74-5.62) 7108/
8496
79 <0.001 1.38 (0.93-2.05)*
PB 17 3133/
5705
66 0.01 11.55 (6.62-20.12)* 3295/
5882
78 <0.001 1.51 (0.88-2.58)* 3563/
6194
85 <0.001 1.90 (1.06-3.39)* 3563/
6194
69 0.002 10.27 (2.42-43.63)* 6726/
11788





67 0.006 15.51 (2.53-94.94)* 3163/
5604
60 0.01 1.34 (0.85-2.11)* 3417/
5906
81 <0.001 1.71 (0.97-3.03)* 3417/
5906
66 0.007 14.20 (2.38-84.61)* 6434/
11212
89 <0.001 2.33 (1.91-2.84)*
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http://www.biomedcentral.com/1471-2407/14/950chromosome 14q21-24 and contains a total of 35 com-
mon SNPs, according to the dbSNP database (http://www.
ncbi.nlm.nih.gov/SNP). Two polymorphisms, C1772T
(rs11549465) and G1790A (rs11549467), result in an
amino acid substitution of proline to serine and alanine to
threonine, respectively, and the present studies show that
C1772T (rs11549465) is not in substantial linkage dis-
equilibrium (LD) with G1790A (rs11549467) (R2 = 0.002).
Under normoxic condition, the hydroxylation of proline
402 and proline 564 occurs within the oxygen-dependent
degradation (ODD) domain of HIF-1α, and HIF-1α is ra-
pidly degraded. The two SNPs examined here are located
within the ODD/pVHL binding domain in exon 12 of the
HIF-1α gene and may enhance the transcription activity
of the HIF-1α gene by causing structural changes, increa-
sing the stability of HIF-1α protein and affecting the
expression of downstream target genes [8,14,17]. Over the
last few years, a great number of studies have been
performed to investigate the association between these
HIF-1α polymorphisms and cancer risk in different popu-
lations. However, the results of these studies remain in-
conclusive. In a meta-analysis conducted by Zhao et al. in
2009 [67], the HIF-1 C1772T polymorphism was reported
to be associated with increased cancer risk, while no
significant association was found between the HIF-1α
G1790A polymorphism and cancer risk. Additionally, Li
et al. reported that the HIF-1α C1772T polymorphism
correlates with urinary cancer risk in Caucasian popula-
tion, and the G1790A polymorphism may increase the risk
of prostate cancer [68]. Due to the important role of
HIF-1α polymorphisms in the development of cancer and
due to the limited statistical power of the previous studies,
we conducted a comprehensive literature search and per-
formed a meta-analysis on all of the available case-control
studies to systematically evaluate the exact relationship
between the C1772T/G1790A polymorphisms in HIF-1α
and cancer susceptibility.
Regarding the HIF-1α C1772T polymorphism, our re-
sults suggested a significant association in four genetic
comparison models, providing convincing evidence that
the HIF-1α C1772T polymorphism may be a risk factor in
cancer development. When sensitivity analyses were per-
formed, the results were similar to those when the studies
with controls not in HWE were included, suggesting that
our results were very robust. Moreover, when the data
were stratified by cancer type, a significant association was
observed between the C1772T polymorphism and breast
cancer in Asians. This may be due to the specific genetic
variant induced over-expression of HIF-1 under hypoxic
condition in breast cancer cells, and the different life style,
ethnicity and body composition between Asians and
Caucasians, which could contribute to the results. A sig-
nificant association was also observed in lung cancer.
When subgroup analyses were performed according toethnicity and source of controls, a significant association
was found in Asian population, Caucasian population and
in hospital-based studies. Zhao et al. [67] reported that
the genotype TT was significantly associated with an in-
creased cancer risk in Asians, but the CI was very wide
due to the lack of mutant homozygotes in Asians. In our
meta-analysis, we also found that the C1772T poly-
morphism was a risk factor in Asians (Dominant model:
OR = 1.29, 95% CI = 1.04-1.58; Allelic model: OR = 1.47,
95% CI = 1.04-1.57). Beyond that, we had not found any
significant associations in prostate cancer, renal cancer or
oral cancer.
For the HIF-1α G1790A polymorphism, the pooled re-
sults from all of the eligible studies suggested that the
G1790A polymorphism in HIF-1α is significantly asso-
ciated with an increased cancer risk in all of the genetic
models. We also conducted subgroup analyses based on
the cancer type, ethnicities and source of controls. In the
subgroup analysis according to cancer type, the results
suggested that the HIF-1α G1790A polymorphism sig-
nificantly increased the risk of lung cancer, renal cancer,
oral cancer and pancreatic cancer, but the CI for the oral
cancer subgroup was very wide. This may be due to the
lack of mutant homozygotes detected, and the asso-
ciation could have been caused by chance. More studies
based on large populations should be prusued. The study
reported by Putra et al. indicated that even though they
did not found any significant differences in genotype for
G1790A between lung cancer patients and healthy con-
trols, however, the G1790A variant allele was signifi-
cantly higher in lung cancer patients, and TP53 LOH
and 1p34 LOH were more frequently observed in indi-
viduals with the HIF-1α G1790A polymorphism, sug-
gesting that this polymorphism may induce mutations in
some tumor suppressor genes involved in lung cancer
development [46]. Here, we found a significant asso-
ciation between the G1790A polymorphism and lung
cancer risk. When the data were stratified according to
ethnicity classification and source of controls, similar to
the C1772T polymorphism, significantly increased risks
were also found in Asian populations, Caucasian po-
pulations and population-based studies. After sensitivity
analyses were performed, our results did not vary sub-
stantially, which strongly suggests an association bet-
ween the HIF-1α G1790A polymorphism and increased
cancer risk. One important factor that could influence
the results is heterogeneity. In our study, significant
heterogeneity existed in the analysis of the heterozygote
model, the dominant model and the allelic model for the
HIF-1α C1772T/G1790A polymorphism. When we per-
formed a subgroup analysis according to cancer type,
ethnicity or source of controls, the heterogeneity was
reduced significantly or disappeared. The significant
heterogeneity may due to the differences in ethnicity or
Figure 3 Overall association between the HIF-1α G1790A polymorphism and cancer risk for all subjects using the dominant model
(GA + AA vs. GG).
Figure 4 The influence of individual studies on the summary odds ratio (OR) for the HIF-1α G1790A polymorphism.
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Figure 5 Begg’s funnel plot for evaluating the publication bias of the meta-analysis for the HIF-1α C1772T polymorphism.
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http://www.biomedcentral.com/1471-2407/14/950cancer types or even in the selection of the controls.
Furthermore, publication bias was not observed in our
meta-analysis of the HIF-1α G1790A/C1772T poly-
morphisms. We also performed a sensitivity analysis to
evaluate the sources of heterogeneity. The pooled ORs
did not vary substantially, indicating that the results of
our meta-analysis are robust and reliable.
To a certain extent, our meta-analysis still includes
several limitations that should be interpreted and taken
into consideration. First, in the era of GWAS, resear-
chers can obtain the GWAS data for these two SNPs
from all cancer studies and conduct a meta-analysis withFigure 6 Begg’s funnel plot for evaluating the publication bias of thethe GWAS data instead of relying on published data,
which may be biased toward positive findings. Second,
the lack of observations concerning gene-gene and gene-
environment interactions could influence our results.
Third, although the total number of studies was not
small, there were still not sufficient eligible studies for
us to analyze different types of cancers, such as colo-
rectal carcinoma, renal cell carcinoma or glioma; more
studies are needed to explore the potential relationship
between HIF-1αC1772T/G1790A polymorphisms and
cancer susceptibility. Forth, the lack of detailed original
data, such as the age and sex of the populations, smokingmeta-analysis for the HIF-1α G1790A polymorphism.
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http://www.biomedcentral.com/1471-2407/14/950status, or alcohol consumption in the eligible studies may
influence our extended analyses. However, our meta-
analysis also has many advantages. First, we searched all
possible publications, and the total number of eligible
studies was much larger than other previously published
meta-analyses; therefore, our results are more convincing.
Second, no publication bias was detected in our meta-
analysis. Finally, all of the data were extracted from well-
selected studies, providing stronger statistical power for
our study.
Conclusions
In conclusion, this meta-analysis provides powerful evi-
dence that both the C1772T and G1790A polymorphisms
in the HIF-1α gene may contribute to individual suscepti-
bility to cancers. It will be necessary to perform additional
research to evaluate the relationship between HIF-1α
C1772T/G1790A polymorphisms and cancer risk. More-
over, large sample case-control studies assessing gene-to-
gene and gene-to-environment interactions are required
to verify these findings.
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